JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response

The Journal of Clinical Investigation +

|

December 1, 2015

|

December 1, 2015

Related Experiment Videos

Contact us if these videos are not relevant.

View abstract on PubMed

Summary

This summary is machine-generated.

Loss of SLAMF1 (CD150) in chronic lymphocytic leukemia (CLL) indicates aggressive disease, shorter treatment times, and reduced survival. SLAMF1 deficiency impacts cell migration and autophagy, affecting drug response in CLL patients.

Area Of Science

  • Immunology
  • Molecular Biology
  • Oncology

Background

  • Chronic lymphocytic leukemia (CLL) exhibits variable clinical courses, necessitating markers for aggressive disease identification.
  • The costimulatory molecule and microbial sensor SLAMF1 (CD150) plays a role in immune cell function.

Purpose Of The Study

  • To investigate the role of SLAMF1 expression in CLL aggressiveness and patient outcomes.
  • To elucidate the functional consequences of SLAMF1 loss in CLL cells, including effects on cell migration and autophagy.

Main Methods

  • Analysis of SLAMF1 expression in CLL patient subsets.
  • In vitro studies using SLAMF1-silenced CLL-like Mec-1 cells.
  • Investigation of signaling pathways, chemotaxis, and autophagy induction upon SLAMF1 ligation.
  • Assessment of drug resistance in SLAMF1-deficient CLL cells.

Main Results

  • SLAMF1 expression loss is observed in a subset of aggressive CLL patients, correlating with shorter time to treatment and reduced survival.
  • SLAMF1 silencing in Mec-1 cells altered pathways involved in cell migration and vesicle trafficking.
  • SLAMF1 deficiency increased CXCR4, CD38, and CD44 expression, enhancing chemotaxis.
  • SLAMF1 ligation induced ROS accumulation, p38/JNK phosphorylation, and promoted autophagy by facilitating Beclin1-VPS34 complex formation.
  • SLAMF1-silenced or SLAMF1(lo) CLL cells showed resistance to fludarabine and ABT-737.

Conclusions

  • Loss of SLAMF1 in CLL modulates pathways critical for cell migration and autophagy.
  • These SLAMF1-associated pathway alterations may contribute to unfavorable clinical outcomes and affect therapeutic responses in CLL.
  • SLAMF1 status could serve as a prognostic marker and influence treatment strategies in CLL.

Related Experiment Videos

Contact us if these videos are not relevant.

Related Concept Videos